Effect of Obesity on the Response to Insulin Therapy in Noninsulin-Dependent Diabetes Mellitus
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
An initial improvement in glycemic control is often followed by gradual deterioration of glycemia during insulin treatment of patients with noninsulin-dependent diabetes mellitus (NIDDM). We examined the causes of such worsening in a 12-month follow-up analysis of 100 insulin-treated NIDDM patients in the Finnish Multicenter Insulin Therapy Study who were treated with either combination therapy with insulin or insulin alone. In the entire study group, glycemic control averaged 9.7 +/- 0.2% at 0 months and 8.0 +/- 0.1%, 8.0 +/- 0.1%, 8.2 +/- 0.1%, and 8.5 +/- 0.2% at 3, 6, 9, and 12 months (P < 0.001 for each time point vs. 0 months). Glycemic control at 12 months was significantly worse than that at 3 (P < 0.001), 6 (P < 0.001), and 9 months (P < 0.02). Baseline body mass index was the most significant predictor of deterioration in glycemic control. During 1 yr, hemoglobin A1c decreased almost 3-fold more (by 1.7 +/- 0.2%; P < 0.001 vs. 0 months) in patients whose baseline weight was below the mean baseline body mass index of 28.1 kg/m2 (nonobese patients) than in those whose weight exceeded 28.1 kg/m2 (obese patients; 0.5 +/- 0.2%; P = NS vs. 0 months; P < 0.01 vs. obese patients). Glycemic control improved similarly over 1 yr in the nonobese subjects and deteriorated similarly in the obese patients regardless of their treatment regimen. Insulin doses, per body weight, were similar in the nonobese and obese patients. The nonobese patients consistently gained less weight during 12 months of combination therapy with insulin (3.5 +/- 0.6 kg at 12 months) than during insulin therapy alone (5.1 +/- 0.6 kg; P < 0.05). The treatment regimen did not influence weight gain in the obese group, who gained 4.4 +/- 1.0 kg during combination therapy with insulin and 4.5 +/- 1.1 kg during insulin therapy alone. We reached the following conclusions: 1) after an initial good response, glycemic control deteriorates more in obese than in nonobese patients with NIDDM; 2) in obese patients, weight gain per se cannot explain the poor glycemic response to combination or insulin therapy, but it may induce a disproportionately large increase in insulin requirements because of greater insulin resistance in the obese than in the nonobese; 3) in nonobese patients, glycemic control improves equally during 1 yr with combination therapy with insulin and insulin alone, but combination therapy with insulin is associated with less weight gain than treatment with insulin alone; 4) weight gain appears harmful, as it is associated with increases in blood pressure and low density lipoprotein cholesterol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
Yki-Järvinen, H., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., Niskanen, L., Rajala, S., Ryysy, L., Salo, S., Seppälä, P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272005 · Cited by 324 · cited 10×
“As insulin concentrations are higher during multiple insulin injection than during combination therapy ( 2 ), it is possible that the tendency toward a greater fall of triglycerides during insulin than combination therapy was due to a greater stimulation of LPL by insulin.”
BackgroundMethodResultSelf-citation
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Insulin‐associated weight gain in diabetes – causes, effects and coping strategies
Russell‐Jones, D., & Khan, R. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00686.x · Cited by 557
Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433
“In the largest of these studies, patients previously treated with sulfonylureas and metformin gained more weight when they received multiple insulin injections than when they received a combination of bedtime insulin, sulfonylurea, and metformin (6, 7).”
BackgroundMethodResultInfluentialSelf-citationCummins, E., Royle, P., Snaith, A., Greene, A., Robertson, L., McIntyre, L., & Waugh, N. (2010) · Health Technology Assessment · doi:10.3310/hta14110 · Cited by 335
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314
“cemic agents (2) and increases the risk of”
BackgroundMäkimattila, S., Nikkilä, K., & Yki-Järvinen, H. (1999) · Diabetologia · doi:10.1007/s001250051172 · Cited by 314
Self-citationCombination therapies with insulin in type 2 diabetes
Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review
Leslie, W. S., Hankey, C. R., & Lean, M. E. J. (2007) · QJM · doi:10.1093/qjmed/hcm044 · Cited by 173
“review (n =43) Papers excluded (n =96) Reasons: Not RCT ( 37 ) Study duration<12 weeks (10) Not adults (1) Combination therapy (5) Weight gain not reported/quantified (30) No comparator (3) Weight self- reported (2) Drug under review not included in study (1) Not drug naive prior to study (2) Duplicate publication (5)”
BackgroundEvidence-based practice guideline for the treatment for diabetes in Japan 2013
Tajima, N., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Fujimoto, K., Sakamoto, M., & Haneda, M. (2015) · Diabetology International · doi:10.1007/s13340-015-0206-2 · Cited by 154
Hanefeld, M., & Sachse, G. (2002) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00237.x · Cited by 151
Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
Obesity Upregulates Genes Involved in Oxidative Phosphorylation in Livers of Diabetic Patients
Takamura, T., Misu, H., Matsuzawa‐Nagata, N., Sakurai, M., Ota, T., Shimizu, A., Kurita, S., Takeshita, Y., Ando, H., Honda, M., et al. (2008) · Obesity · doi:10.1038/oby.2008.419 · Cited by 96
“In patients with diabetes, the coexistence of obesity further increases insulin resistance and makes glycemic control difficult (2).”
BackgroundEvaluation of the lack of anorectic effect of intracerebroventricular insulin in rats
Jessen, L., Clegg, D. J., & Bouman, S. D. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90736.2008 · Cited by 29
Metadata
- Authors
- Yki-Järvinen, H., Ryysy, L., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., Niskanen, L., Rajala, S., Salo, S., Seppälä, P., Tulokas, T., Viikari, J., & Taskinen, M.-R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-12
- Volume
- 82
- Issue
- 12
- Pages
- 4037-4043
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2171620569
- Cited by
- 118
- References
- 3
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.